Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 18/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | BLM | P54132 | 1/20 | 0.62 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.62 |
| ▸ | RECQL | P46063 | 1/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14027180 | 0.78 | PARP1 (0.62) | PARP1ALDH1A1HSD17B10KDM4ELMNA | |
| SCHEMBL31743106 | 0.77 | PARP1 (0.60) | PARP1ALDH1A1HSD17B10KDM4ELMNA | |
| SCHEMBL832144 | 0.77 | PARP1 (0.60) | PARP1ALDH1A1HSD17B10KDM4ELMNA | |
| SCHEMBL29488098 | 0.77 | PARP1 (0.60) | PARP1ALDH1A1HSD17B10KDM4ELMNA | |
| SCHEMBL30033470 | 0.77 | PARP1 (0.60) | PARP1ALDH1A1HSD17B10KDM4ELMNA | |
| SCHEMBL2172575 | 0.77 | PARP1 (1.00) | PARP1ALDH1A1HSD17B10KDM4ELMNA | |
| SCHEMBL12463821 | 0.77 | PARP1 (0.60) | PARP1ALDH1A1HSD17B10KDM4ELMNA | |
| SCHEMBL1536658 | 0.77 | PARP1 (0.60) | PARP1ALDH1A1HSD17B10KDM4ELMNA | |
| SCHEMBL29492688 | 0.77 | PARP1 (1.00) | PARP1ALDH1A1HSD17B10KDM4ELMNA | |
| SCHEMBL29519573 | 0.77 | PARP1 (1.00) | PARP1ALDH1A1HSD17B10KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3409667-B1 | AMIDE COMPOUNDS FOR THE TREATMENT OF HIV INFECTIONS | GILEAD SCIENCES INC (US) | 2021-07-21 | — | — | EP | disclosed |
| EP-2961742-B1 | AMIDE COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES INC (US) | 2018-08-01 | — | — | EP | disclosed |
| EP-2124562-B1 | BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF | SECOND GENOME INC (US) | 2016-04-20 | — | — | EP | disclosed |
| US-8093265-B2 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-8030320-B2 | Derivatives of 1-OXO-1,2-dihydroisoquinoline-5-carboxamides and of 4-OXO-3,4-dihydroquinazoline-8-carboxamides, preparation thereof and application thereof in therapeutics | SANOFI-AVENTIS (FR) | 2011-10-04 | — | — | US | disclosed |
| US-8030320-B2 | Derivatives of 1-OXO-1,2-dihydroisoquinoline-5-carboxamides and of 4-OXO-3,4-dihydroquinazoline-8-carboxamides, preparation thereof and application thereof in therapeutics | SANOFI-AVENTIS (FR) | 2011-10-04 | — | — | US | disclosed |
| US-8030320-B2 | Derivatives of 1-OXO-1,2-dihydroisoquinoline-5-carboxamides and of 4-OXO-3,4-dihydroquinazoline-8-carboxamides, preparation thereof and application thereof in therapeutics | SANOFI-AVENTIS (FR) | 2011-10-04 | — | — | US | disclosed |
| US-20100197706-A1 | DERIVATIVES OF 1-OXO-1,2-DIHYDROISOQUINOLINE-5-CARBOXAMIDES AND OF 4-OXO-3,4-DIHYDROQUINAZOLINE-8-CARBOXAMIDES, PREPARATION THEREOF AND APPLICATION THEREOF IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2010-08-05 | — | — | US | disclosed |
| US-20100197706-A1 | DERIVATIVES OF 1-OXO-1,2-DIHYDROISOQUINOLINE-5-CARBOXAMIDES AND OF 4-OXO-3,4-DIHYDROQUINAZOLINE-8-CARBOXAMIDES, PREPARATION THEREOF AND APPLICATION THEREOF IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2010-08-05 | — | — | US | disclosed |
| US-20100197706-A1 | DERIVATIVES OF 1-OXO-1,2-DIHYDROISOQUINOLINE-5-CARBOXAMIDES AND OF 4-OXO-3,4-DIHYDROQUINAZOLINE-8-CARBOXAMIDES, PREPARATION THEREOF AND APPLICATION THEREOF IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2010-08-05 | — | — | US | disclosed |
| EP-2185523-A2 | DERIVATIVES OF 1-OXO-1,2-DIHYDROISOQUINOLINE-5-CARBOXAMIDES AND OF 4-OXO-3,4-DIHYDROQUINAZOLINE-8-CARBOXAMIDES, PREPARATION THEREOF AND APPLICATION THEREOF IN THERAPEUTICS | Sanofi-Aventis (FR) | 2010-05-19 | — | — | EP | disclosed |
| WO-2009044018-A2 | DERIVATIVES OF 1-OXO-1,2-DIHYDROISOQUINOLINE-5-CARBOXAMIDES AND OF 4-OXO-3,4-DIHYDROQUINAZOLINE-8-CARBOXAMIDES, PREPARATION THEREOF AND APPLICATION THEREOF IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2009-04-09 | — | — | WO | disclosed |
| WO-2009044018-A2 | DERIVATIVES OF 1-OXO-1,2-DIHYDROISOQUINOLINE-5-CARBOXAMIDES AND OF 4-OXO-3,4-DIHYDROQUINAZOLINE-8-CARBOXAMIDES, PREPARATION THEREOF AND APPLICATION THEREOF IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2009-04-09 | — | — | WO | disclosed |
| US-20080287415-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | SECOND GENOME, INC. | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197706-A1 | DERIVATIVES OF 1-OXO-1,2-DIHYDROISOQUINOLINE-5-CARBOXAMIDES AND OF 4-OXO-3,4-DIHYDROQUINAZOLINE-8-CARBOXAMIDES, PREPARATION THEREOF AND APPLICATION THEREOF IN THERAPEUTICS | BRD4, CNR2, AADAC | PARP1 366/4885ALDH1A1 526/4885HSD17B10 3800/4885 |
| US-20080287415-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | P2RX7, P2RX3, P2RX2 | PARP1 1735/4885ALDH1A1 3335/4885HSD17B10 4051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.